ME02307B - Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol- 3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr - Google Patents
Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol- 3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfrInfo
- Publication number
- ME02307B ME02307B MEP-2015-198A MEP19815A ME02307B ME 02307 B ME02307 B ME 02307B ME P19815 A MEP19815 A ME P19815A ME 02307 B ME02307 B ME 02307B
- Authority
- ME
- Montenegro
- Prior art keywords
- dichloropyrtdtn
- indazol
- ethoxy
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38991110P | 2010-10-05 | 2010-10-05 | |
PCT/US2011/053798 WO2012047699A1 (en) | 2010-10-05 | 2011-09-29 | Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor |
EP11771312.3A EP2625175B1 (en) | 2010-10-05 | 2011-09-29 | Crystalline (r)-(e)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h-indazol-3-yl)vinyl)-1h-pyrazol-1-yl)ethanol and its use as fgfr inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
ME02307B true ME02307B (me) | 2016-06-20 |
Family
ID=44999860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-2015-198A ME02307B (me) | 2010-10-05 | 2011-09-29 | Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol- 3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr |
Country Status (35)
Country | Link |
---|---|
US (1) | US8530665B2 (me) |
EP (1) | EP2625175B1 (me) |
JP (1) | JP5940547B2 (me) |
KR (1) | KR101527661B1 (me) |
CN (1) | CN103153983B (me) |
AR (1) | AR083091A1 (me) |
AU (1) | AU2011312485B2 (me) |
BR (1) | BR112013006336A2 (me) |
CA (1) | CA2813329C (me) |
CL (1) | CL2013000884A1 (me) |
CO (1) | CO6710911A2 (me) |
DK (1) | DK2625175T3 (me) |
DO (1) | DOP2013000072A (me) |
EA (1) | EA021817B1 (me) |
EC (1) | ECSP13012539A (me) |
ES (1) | ES2558777T3 (me) |
HK (1) | HK1184147A1 (me) |
HR (1) | HRP20151299T1 (me) |
HU (1) | HUE026379T2 (me) |
IL (1) | IL224850A (me) |
JO (1) | JO3062B1 (me) |
MA (1) | MA34552B1 (me) |
ME (1) | ME02307B (me) |
MX (1) | MX2013003907A (me) |
NZ (1) | NZ608482A (me) |
PE (1) | PE20140252A1 (me) |
PL (1) | PL2625175T3 (me) |
PT (1) | PT2625175E (me) |
RS (1) | RS54457B1 (me) |
SG (1) | SG188286A1 (me) |
SI (1) | SI2625175T1 (me) |
TW (1) | TWI418554B (me) |
UA (1) | UA111725C2 (me) |
WO (1) | WO2012047699A1 (me) |
ZA (1) | ZA201301560B (me) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19945982A1 (de) * | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
KR102406771B1 (ko) | 2012-06-13 | 2022-06-13 | 인사이트 홀딩스 코포레이션 | Fgfr 억제제로서 치환된 트리사이클릭 화합물 |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
EP3318564B1 (en) | 2013-04-19 | 2021-07-28 | Incyte Holdings Corporation | Bicyclic heterocycles as fgfr inhibitors |
CN103819396B (zh) * | 2014-02-26 | 2016-06-15 | 四川大学 | 一种手性的1-(3,5-二氯吡啶-4-基)-乙醇的合成方法 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
DK3788047T3 (da) | 2018-05-04 | 2024-09-16 | Incyte Corp | Faste former af en FGFR-inhibitor og fremgangsmåder til fremstilling deraf |
MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
CN115151539A (zh) | 2019-12-04 | 2022-10-04 | 因赛特公司 | Fgfr抑制剂的衍生物 |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN111705099B (zh) * | 2020-07-01 | 2022-03-08 | 天津药明康德新药开发有限公司 | 一种(s)-1-(3,5-二氯吡啶-4-取代)乙醇的制备方法 |
US20240182487A1 (en) * | 2020-12-17 | 2024-06-06 | Blossomhill Therapeutics, Inc. | Macrocycles and their use |
JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法 |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
SG129306A1 (en) * | 2000-09-11 | 2007-02-26 | Chiron Corp | Quinolinone derivatives as tyrosine kinase inhibitors |
AU2003241925A1 (en) | 2002-05-31 | 2003-12-19 | Eisai R&D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
JP2007529500A (ja) * | 2004-03-17 | 2007-10-25 | ファイザー・インク | 2,5−ジメチル−2h−ピラゾール−3−カルボン酸{2−フルオロ−5−[3−((e)−2−ピリジン−2−イル−ビニル)−1h−インダゾール−6−イルアミノ]−フェニル}−アミドの多形及び非結晶形 |
JP4746299B2 (ja) * | 2004-07-16 | 2011-08-10 | ジュズ インターナショナル ピーティーイー エルティーディー | 金属酸化物粉末の製造方法 |
JP2006163651A (ja) | 2004-12-03 | 2006-06-22 | Sony Computer Entertainment Inc | 表示装置、表示装置の制御方法、プログラム及びフォントデータ |
US20060160863A1 (en) * | 2005-01-05 | 2006-07-20 | Agouron Pharmaceuticals, Inc. | Polymorphic and amorphous forms of 2-{3-[(E)-2-(4,6-dimethyl-pyridin-2-yl)-vinyl]-1H-indazol-6-ylamino}-N-(4-hydroxy-but-2-ynyl)benzamide |
WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
ES2634866T5 (es) * | 2007-04-05 | 2024-03-04 | Pfizer Prod Inc | Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-[2-(piridin-2-il)etenil]indazol adecuadas para el tratamiento del crecimiento celular anormal en mamíferos |
AR078411A1 (es) * | 2009-05-07 | 2011-11-09 | Lilly Co Eli | Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende |
-
2011
- 2011-09-22 JO JOP/2011/0294A patent/JO3062B1/ar active
- 2011-09-23 TW TW100134428A patent/TWI418554B/zh not_active IP Right Cessation
- 2011-09-23 AR ARP110103482A patent/AR083091A1/es unknown
- 2011-09-29 SI SI201130673T patent/SI2625175T1/sl unknown
- 2011-09-29 JP JP2013532838A patent/JP5940547B2/ja not_active Expired - Fee Related
- 2011-09-29 DK DK11771312.3T patent/DK2625175T3/en active
- 2011-09-29 KR KR1020137008655A patent/KR101527661B1/ko not_active IP Right Cessation
- 2011-09-29 AU AU2011312485A patent/AU2011312485B2/en not_active Ceased
- 2011-09-29 EA EA201390275A patent/EA021817B1/ru not_active IP Right Cessation
- 2011-09-29 EP EP11771312.3A patent/EP2625175B1/en active Active
- 2011-09-29 NZ NZ608482A patent/NZ608482A/en not_active IP Right Cessation
- 2011-09-29 ME MEP-2015-198A patent/ME02307B/me unknown
- 2011-09-29 HU HUE11771312A patent/HUE026379T2/en unknown
- 2011-09-29 US US13/248,055 patent/US8530665B2/en not_active Expired - Fee Related
- 2011-09-29 PE PE2013000789A patent/PE20140252A1/es not_active Application Discontinuation
- 2011-09-29 CA CA2813329A patent/CA2813329C/en not_active Expired - Fee Related
- 2011-09-29 CN CN201180048148.7A patent/CN103153983B/zh not_active Expired - Fee Related
- 2011-09-29 RS RS20150828A patent/RS54457B1/en unknown
- 2011-09-29 MA MA35780A patent/MA34552B1/fr unknown
- 2011-09-29 ES ES11771312.3T patent/ES2558777T3/es active Active
- 2011-09-29 WO PCT/US2011/053798 patent/WO2012047699A1/en active Application Filing
- 2011-09-29 UA UAA201303378A patent/UA111725C2/uk unknown
- 2011-09-29 SG SG2013013743A patent/SG188286A1/en unknown
- 2011-09-29 BR BR112013006336A patent/BR112013006336A2/pt not_active IP Right Cessation
- 2011-09-29 MX MX2013003907A patent/MX2013003907A/es active IP Right Grant
- 2011-09-29 PT PT117713123T patent/PT2625175E/pt unknown
- 2011-09-29 PL PL11771312T patent/PL2625175T3/pl unknown
-
2013
- 2013-02-21 IL IL224850A patent/IL224850A/en not_active IP Right Cessation
- 2013-02-28 ZA ZA2013/01560A patent/ZA201301560B/en unknown
- 2013-04-02 DO DO2013000072A patent/DOP2013000072A/es unknown
- 2013-04-02 CL CL2013000884A patent/CL2013000884A1/es unknown
- 2013-04-03 EC ECSP13012539 patent/ECSP13012539A/es unknown
- 2013-04-08 CO CO13090555A patent/CO6710911A2/es unknown
- 2013-10-15 HK HK13111594.2A patent/HK1184147A1/xx not_active IP Right Cessation
-
2015
- 2015-11-30 HR HRP20151299TT patent/HRP20151299T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ME02307B (me) | Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol- 3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr | |
IL269977B (en) | Compounds 2-(1-isopropyl-pyrazol-5-yl)-3-(hydroxy/chloro)methyl pyridine | |
HK1226069A1 (zh) | 3,5 -二氨基-6-氯-n-(n-(4 -(4 -(2 -(己基(2,3,4,5,6 -五羥基己基)氨基)乙氧基)苯基)丁基)甲脒基)吡嗪-2-甲醯胺 | |
IL242279A0 (en) | Compounds of 3-chloro-3]-n-(pyrimidine-2-ylamino)phenyl]substituted propanamide and their salts | |
IL229954A0 (en) | Fungicidal mutated compounds of 1 – {2 – [2 – halo – 4 – (4 – halogen – phenoxy) – phenyl] – 2 – alkoxy – 2 – cyclyl – ethyl} – 1h [4,2,1]triazole | |
ZA201108541B (en) | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1hpyrazol-1yl]octane-or heptane-nitrile as jak inhibitors | |
HK1206732A1 (en) | Liquid formulations of salts of 1-[2-(2,4- dimethylphenylsulfanyl)pheny]piperazine 1-[2-(24-)] | |
ZA201003909B (en) | Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydopyran-4-yl)-propionamide | |
DK2878598T3 (da) | Krystallinsk form af 4-[5-(pyridin-4-yl)-1h-1,2,4-triazol-3-yl]pyridin-2-carbonitril | |
IL220851A (en) | Process for the preparation of n - (2 - (2 - (4 - (2 - (7,6-dimethoxy-4,3-dihydro-iso-quinoline-2 - (1 h))) ethyl) phenyl) - h2 - tetrazole - 5-ram (5,4-dimethoxyphenyl) -4-oxo-h4-chromium-2-carboxamide methane-sulfonate, its intermediate and intermediate preparation process | |
PL2722046T3 (pl) | Postać krystaliczna 1 2-((R)-2-metylopirolidyn-2-ylo)-1H-benzoimidazolo-4-karboksyamidu | |
SI2608789T1 (sl) | Terapevtske uporabe 1-(2-(2,4-dimetil-fenilsulfanil) fenil) piperazina | |
TH132151A (th) | ((r)-(e)-2-(4-(2-(5-(1-(3,5-ไดคลอโรไพริดิน-4-อิล)เอทธอกซี)-1h-อินดาซอล-3-อิล)ไวนิล)-1h-ไพราซอล-1-อิล)เอทธานอลเชิงผลึก | |
TH132151B (th) | ((r)-(e)-2-(4-2-(5-(1-(3,5-ไดคลอโรไพริดิน-4-อิล)เอทธอกซี)-1 h-อินดาซอล-3- อิล)ไวนิล)-1 h-ไพราซอล-1-อิล)เอทธานอลเชิงผลึก | |
PL393335A1 (pl) | Nowe E-1,2-bis{4-[(2-(1-oxo-alkilo)-3-oxo-alkilo]fenylo) eteny oraz sposób ich otrzymywania |